Aquestive Therapeutics, Inc. financial data

Symbol
AQST on Nasdaq
Location
Warren, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 478 % -11.9%
Quick Ratio 34.1 % -21.8%
Debt-to-equity -333 % -16.7%
Return On Equity 140 % +122%
Return On Assets -59.9 % -76.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 122M shares +33.8%
Common Stock, Shares, Outstanding 122M shares +33.4%
Entity Public Float 207M USD +151%
Common Stock, Value, Issued 121K USD +33%
Weighted Average Number of Shares Outstanding, Basic 111M shares +21.4%
Weighted Average Number of Shares Outstanding, Diluted 111M shares +21.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 43.4M USD -26.3%
Research and Development Expense 18.9M USD +3.63%
Costs and Expenses 99.2M USD +24%
Operating Income (Loss) -55.8M USD -164%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -69M USD -96.6%
Income Tax Expense (Benefit) -14K USD -114%
Net Income (Loss) Attributable to Parent -69M USD -96%
Earnings Per Share, Basic 0 USD/shares -45.8%
Earnings Per Share, Diluted 0 USD/shares -59.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 129M USD +65.7%
Inventory, Net 7.88M USD +12.3%
Assets, Current 152M USD +57.1%
Property, Plant and Equipment, Net 3.92M USD +1.82%
Operating Lease, Right-of-Use Asset 4.77M USD -10.2%
Other Assets, Noncurrent 3.2M USD -24.4%
Assets 164M USD +48.7%
Accounts Payable, Current 10.9M USD +43.5%
Employee-related Liabilities, Current 3.69M USD +6.86%
Accrued Liabilities, Current 5.13M USD +2.05%
Contract with Customer, Liability, Current 1.09M USD +4.2%
Liabilities, Current 25.6M USD +68.8%
Long-term Debt and Lease Obligation 32.5M USD +18.1%
Contract with Customer, Liability, Noncurrent 19.7M USD -2.98%
Operating Lease, Liability, Noncurrent 4.51M USD -11.8%
Other Liabilities, Noncurrent 2.06M USD +1.23%
Liabilities 168M USD +7.91%
Retained Earnings (Accumulated Deficit) -415M USD -19.9%
Stockholders' Equity Attributable to Parent -4.11M USD +91%
Liabilities and Equity 164M USD +48.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.4M USD -125%
Net Cash Provided by (Used in) Financing Activities 20.6M USD -74.7%
Net Cash Provided by (Used in) Investing Activities -135K USD -366%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 122M shares +33.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.89M USD -104%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 129M USD +65.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1M USD -31.6%
Deferred Tax Assets, Valuation Allowance 94.6M USD +12.5%
Deferred Tax Assets, Gross 95.3M USD +12.6%
Operating Lease, Liability 5.11M USD -8.62%
Depreciation 566K USD -36.5%
Payments to Acquire Property, Plant, and Equipment 135K USD +366%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -69M USD -96%
Lessee, Operating Lease, Liability, to be Paid 8.09M USD -13.6%
Property, Plant and Equipment, Gross 47.8M USD +1.29%
Operating Lease, Liability, Current 601K USD +24.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.35M USD +2.12%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.32M USD +2.65%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.98M USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.18M USD -12.3%
Deferred Tax Assets, Operating Loss Carryforwards 34.7M USD +27.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.18M USD -11.1%
Additional Paid in Capital 411M USD +36.7%
Amortization of Intangible Assets 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 8.65M USD +54%
Interest Expense 9.09M USD +48.9%